Mirvetuximab soravtansine (Elahere)

At a glance

Mirvetuximab soravtansine (Elahere) is an antibody–drug conjugate, often shortened to ADC. It combines an antibody that recognises a target on cells with a cell-killing medicine. It is given by a trained team through a drip into a vein. Although it is targeted treatment, it can affect healthy tissues and needs careful monitoring.

Eye care is a central part of Elahere treatment. Eye examinations and the correct drops help the team detect and manage changes to the surface of the eye. The US and EU instructions are not identical, so obtain one clear schedule from your treating team and eye specialist before the first infusion.

Follow your own treatment calendar and the advice from your care team. Keep your medicine names and treatment dates handy to share with other clinicians.

How it works

The antibody recognises folate receptor-alpha, abbreviated FRα. After the conjugate enters a target-bearing cell, it releases DM4, a substance that disrupts the internal structures needed for cell division. This is different from taking folic acid or an ordinary vitamin supplement; changing dietary folate does not replace the treatment or its selection test.

The antibody, its chemical link and the attached medicine form one product. They are not separate medicines that you can take in different amounts yourself. Targeting helps deliver treatment to particular cells, but it does not mean that only cancer cells are affected. Side effects can come from the attached medicine, the antibody, your existing illness or accompanying treatment.

An ADC is different from an immune checkpoint inhibitor, even when both are given in the same treatment plan. A reaction or noticeable side effect is not proof that an ADC is working. Equally, having few side effects does not mean that treatment has failed.

Is this treatment suitable for me?

Mirvetuximab soravtansine is used for selected folate receptor-alpha (FRα)-positive, platinum-resistant ovarian, fallopian-tube or primary peritoneal cancers after one to three previous systemic treatments. The exact tumour type and tissue-test criteria must meet the treatment requirements. Your oncologist will advise whether it is suitable for you, taking account of your cancer type, relevant test results, previous treatment, overall health and the applicable prescribing information and regulatory guidance in your country.

A validated tissue test assesses FRα expression. The required result and the other eligibility criteria must fit the applicable treatment guidance. The team also considers existing eye disease, nerve symptoms, lung disease and liver function. A positive target test alone does not establish that treatment is suitable. Treatment should be avoided in moderate or severe liver impairment.

The discussion should cover the aim of treatment, the alternatives, likely appointments and how benefit will be assessed. A target found in a sample is one part of this decision; it does not guarantee a response. Tell the team what matters to you, including independence, work, caring responsibilities and the practical support available at home.

Before treatment

Bring a complete list of prescribed and non-prescribed medicines, vitamins, herbal products and allergies. Mention previous difficult reactions to infusions, infections, diabetes, liver or kidney problems and any pregnancy or breastfeeding. Explain symptoms you already have so a later change is easier to recognise.

An eye specialist checks vision and examines the eye surface with a slit lamp before treatment. Describe dry eyes, previous eye operations, corneal disease and any contact-lens use. Blood counts and liver and kidney tests are reviewed. Pregnancy status is checked before starting if pregnancy is possible. Existing numbness, tingling, cough or breathlessness should be recorded so changes can be recognised.

A nurse or pharmacist should explain the supportive medicines and which ones start before the treatment day. Ask your team to help you plan when to take each medicine. Make sure you know how to reach your hospital's urgent oncology service outside clinic hours. You may find it helpful to save the instructions on your phone or keep a copy at home. A family member or friend can help you remember them.

Discuss fertility preservation before treatment if future parenthood matters to you. Tell the team about dental problems and planned procedures. A procedure may need to be timed around blood counts and infection risk. Do not postpone reporting an active dental infection while waiting for the next routine appointment.

How treatment is given

The usual dose is 6 mg/kg of adjusted ideal body weight every three weeks. This is a specific calculation using height and weight, not simply your measured body weight multiplied by six. The pharmacy team calculates it. Infusion speed is increased cautiously according to tolerance; later infusions may run at the previously tolerated rate. The total appointment time depends on the calculated dose, infusion rate and monitoring.

Premedicines include a corticosteroid, an antihistamine, a fever-reducing medicine and anti-sickness treatment. Eye drops are a separate part of the plan. Under US instructions, prescribed steroid drops are used six times daily from the day before infusion through day 4, then four times daily on days 5–8. Lubricating drops are used at least four times daily during treatment, with at least ten minutes between the steroid and lubricant. Do not start or renew steroid drops without the prescribed eye-care supervision.

EU instructions use lubricants throughout treatment and recommend steroid drops as secondary prevention in subsequent cycles after specified corneal toxicity, when the eye specialist considers them appropriate. That schedule starts on the infusion day and continues for the next seven days, with at least 15 minutes before lubricant drops. Your team should explain which product instructions and individual plan apply; do not combine two schedules yourself.

Treatment is delivered through a cannula in a vein, a central line or an implanted port, depending on the plan and available access. Staff check the medicine, your identity, blood results and recent symptoms before starting. The appointment includes preparation and monitoring, so it will usually take longer than the infusion itself.

Tell the nurse immediately if you notice burning, pain, swelling, redness, leakage or tightness around the infusion site. These can mean medicine is leaking outside the vein. Do not wait for the drip to finish. At home, report a site that becomes more painful, blistered or discoloured, even if it looked normal when you left.

Also report flushing, itching, shivering, chest or back discomfort, wheezing, dizziness or swelling during treatment. Staff can stop or slow the infusion and assess you. Do not adjust the pump or line yourself. If a line remains in place, follow its cleaning and dressing instructions and report fever, tenderness or drainage around it.

If an appointment is missed, contact the treatment unit to arrange the next dose. Do not simply wait for the following cycle or seek an extra dose elsewhere. The correct restart date depends on why the dose was missed, the treatment schedule and recovery from side effects.

Monitoring your treatment

Blood tests usually check infection-fighting cells, red cells, platelets, kidney function and liver function. Some abnormalities cause no early symptoms. A reassuring blood test does not make a new symptom safe to ignore, and feeling well is not a reason to miss monitoring.

US instructions call for an eye examination before treatment and every other cycle for the first eight cycles, then as clinically indicated. EU instructions require baseline assessment and assessment for new or worsening eye symptoms before the next dose; significant ocular reactions require additional examinations at least every other cycle until recovery. The treating team may arrange more frequent review. Vision changes can require a treatment pause or dose reduction. Blood tests and checks for nerve or lung symptoms continue alongside response assessments.

Your team compares examinations, symptoms and relevant scans or disease tests over time. Ask when the first response assessment is planned and what the result could change. A treatment break or lower dose may protect you from accumulating harm while allowing further treatment. It is not automatically evidence that the cancer has worsened. Never try to compensate for a reduced dose with supplements or closer appointments.

Common side effects

Side effects vary between people and between treatment combinations. You may experience several, a few or none of those described. Tell the team about symptoms that interfere with eating, sleeping, walking or usual tasks; a problem does not need to be severe before support is worthwhile.

Blurred vision and dry eyes

Vision may blur, eyes may feel gritty or dry, and light may become uncomfortable. Report changes promptly, even when using the prescribed drops. Avoid contact lenses unless the eye specialist permits them. Glasses and sunglasses may improve comfort but do not replace an examination. Do not drive with impaired vision.

Tingling, numbness and discomfort

Peripheral neuropathy affects nerves in the hands and feet. Tell the team early about tingling, burning, reduced sensation, weakness or problems with buttons and balance. A dose change can be needed before symptoms become disabling. Use supportive footwear and check numb skin for unnoticed injury.

Digestive symptoms

Nausea, vomiting, constipation, diarrhoea and abdominal discomfort can occur. Use preventive anti-sickness medicines and report problems that limit intake. Persistent vomiting with a swollen painful abdomen or inability to pass stool or wind needs urgent assessment rather than repeated laxatives.

Tiredness and reduced stamina

Plan important tasks for the part of the day when you have most energy and accept practical help. Short periods of gentle activity can be useful, with rest between them. Sudden marked weakness, breathlessness, dizziness or a racing heart needs assessment for causes such as anaemia, infection or dehydration. Do not assume every new limitation is ordinary treatment fatigue.

Nausea, appetite and bowel changes

Take prescribed anti-sickness medicines on the agreed schedule. Small regular meals, cool foods and frequent sips can be easier to manage. Tell the team if you cannot keep medicines or fluids down, are passing little urine or are losing weight. A dietitian can help when eating becomes difficult.

Record loose stools and whether there is pain, blood or fever. Severe diarrhoea, repeated vomiting or a swollen painful abdomen needs prompt advice. Constipation can be worsened by anti-sickness drugs and pain relief; use the bowel plan your team recommends. Do not repeatedly add laxatives or anti-diarrhoeal medicines without checking when there is significant pain or other new illness.

Low blood counts

A low white cell count can make infection progress quickly. Follow the urgent-help instructions below. Low red cells can cause tiredness, pallor or breathlessness; sometimes transfusions are needed. Low platelets can cause easy bruising, nosebleeds, bleeding gums or tiny red-purple spots. Report new bleeding and avoid starting aspirin or anti-inflammatory painkillers without checking. Do not stop a prescribed blood thinner yourself; the team must balance bleeding and clotting risks.

Mouth comfort and skin care

Use a soft toothbrush and the mouth-care products advised by your team. Report ulcers, white patches or soreness that limits eating, because infection or dehydration may need treatment. Avoid very hot, acidic or spicy foods if they sting. Moisturise dry skin with a simple fragrance-free product and protect it from strong sunlight. Painful skin, blisters or rapidly worsening redness need medical assessment rather than a new cosmetic product.

Important side effects

Significant eye injury

Elahere can affect the cornea, the clear front surface of the eye, and can cause other ocular inflammation. Severe pain, marked light sensitivity or a sudden deterioration in vision requires urgent assessment. Do not assume every change is simple dryness or wait for the next scheduled eye appointment. Steroid drops themselves need supervision because prolonged or inappropriate use can cause eye complications.

Lung inflammation

Pneumonitis is inflammation of lung tissue and can be serious. Report a new cough, breathlessness, fever or reduced ability to do usual activities promptly. The team must distinguish treatment-related inflammation from infection and other causes. The team withholds treatment for persistent or recurrent moderate pneumonitis and permanently stops it for severe pneumonitis; steroids may be prescribed.

Worsening nerve damage

Neuropathy can accumulate with treatment. New weakness, difficulty walking or loss of hand function needs prompt review. It may take time to improve after a pause and may not completely resolve, which is why early reporting matters. Moderate neuropathy requires a treatment pause and dose reduction after recovery; severe neuropathy requires permanent discontinuation.

Severe infection or an allergic reaction

A serious infection can occur even without a high temperature, especially if steroids or fever-reducing medicines are being taken. New confusion, marked drowsiness, rapid breathing or collapse requires emergency care. Sudden throat swelling, severe wheezing or faintness can indicate a severe allergic reaction. These symptoms should not be managed by waiting at home for the next scheduled review.

Other medicines and vaccinations

Strong inhibitors of CYP3A4, an enzyme involved in handling the payload, may increase side effects. Examples include some antifungals, antibiotics and antiviral medicines. Strong enzyme inducers, such as rifampicin, carbamazepine and phenytoin, may reduce payload exposure and also need checking. The pharmacist should check the exact product rather than having you stop an essential medicine yourself. Tell the eye specialist about every eye drop, including non-prescription products.

Ask the oncology pharmacist to check new prescriptions, over-the-counter remedies and herbal or traditional products. Products described as natural are not necessarily safe with cancer treatment. Do not use an unproven supplement in place of an essential supportive medicine. Keep the team informed about medicines prescribed by other specialists so that advice is coordinated.

Discuss influenza, COVID-19 and other vaccines with the team. Non-live vaccines may be suitable, although the response can be reduced during treatment. Live vaccines require specific specialist advice. Timing after treatment depends on immune recovery and the complete regimen; there is no single waiting interval that is correct for every ADC-treated patient.

Everyday life

Eating does not determine absorption of this intravenous medicine. Aim for enough food and fluids, adjusting for nausea and following any kidney, heart or diabetes restrictions. Avoid a restrictive anticancer diet that causes weight loss. Discuss alcohol with the team, particularly if liver tests are abnormal or other medicines cause sedation.

Work may remain possible with flexible hours and time for appointments. Increase activity gradually and avoid tasks that become unsafe because of fatigue, poor balance or impaired vision. Do not drive if dizzy, sleepy, visually affected or unable to use the pedals safely. Sedating premedicines can also affect driving, so arrange transport for early appointments until you know the plan.

Keep an eye-drop calendar and bring the bottles or a current list to appointments. If several drops are prescribed, record their order and spacing. Do not let the bottle tip touch the eye or share bottles. Arrange help with transport and small-print tasks when vision fluctuates.

Discuss travel before booking, especially long journeys or travel far from urgent care. Carry your treatment summary and enough supportive medicines. Use careful hand hygiene and food safety; avoid close contact with people who are clearly infectious. Complete social isolation is not automatically required. Ask about additional precautions when blood counts are very low.

Sex is often possible if comfortable, with the pregnancy precautions below and any advice about infection or bleeding. Ask the team whether barrier protection is needed after a dose to reduce exposure to drug residues in body fluids; the interval depends on the treatment. Caregivers cleaning urine, stool or vomit should follow the unit's handling advice, wear gloves when instructed and wash their hands afterwards. Keep medicines away from children and pets.

Fertility, pregnancy and breastfeeding

Use effective contraception during treatment and for at least seven months after the final dose if you could become pregnant. Do not breastfeed during treatment or for at least one month afterwards. Discuss fertility before starting; absence of periods does not make contraception unnecessary.

Pregnancy should be discussed before treatment and reported promptly if it occurs or is suspected. Loss of periods does not reliably mean pregnancy is impossible. Vomiting or severe diarrhoea can interfere with oral contraception; seek advice about additional protection if this happens. Accompanying medicines may require longer precautions than the ADC itself, so obtain one clear end date for the complete regimen.

Fertility may be affected by treatment and previous therapies, and recovery cannot be guaranteed. Discuss sperm, egg or embryo preservation before starting when feasible. The interval for avoiding pregnancy is a safety precaution and does not itself establish whether fertility has recovered.

After treatment

Continue eye follow-up until symptoms and examination findings have recovered as advised. Ask when each eye drop should stop; the steroid and lubricant may have different end dates. Persistent neuropathy or breathing symptoms also need review after infusions have finished.

Keep attending the recommended blood tests, scans and clinical reviews. Retain a treatment summary with the exact ADC name, dates, significant reactions and any ongoing medication. Tell new clinicians about past treatment when an unexplained symptom is assessed. Continue contraception, breastfeeding restrictions and prescribed supportive medicines for their own specified periods, counted from the relevant final dose.

Recovery can be gradual and may involve physical rehabilitation, dietary support or help with anxiety and sleep. A follow-up visit is also an opportunity to discuss returning to work, travel and persistent symptoms. New severe symptoms still need urgent assessment between appointments; finishing treatment does not remove the need for the urgent-care plan.

Common questions